341 related articles for article (PubMed ID: 32423178)
1. Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals.
Evans BJ; King AT; Katsifis A; Matesic L; Jamie JF
Molecules; 2020 May; 25(10):. PubMed ID: 32423178
[TBL] [Abstract][Full Text] [Related]
2. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization.
Gentilucci L; De Marco R; Cerisoli L
Curr Pharm Des; 2010; 16(28):3185-203. PubMed ID: 20687878
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of
Bendre S; Zhang Z; Kuo HT; Rousseau J; Zhang C; Merkens H; Roxin Á; Bénard F; Lin KS
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854201
[TBL] [Abstract][Full Text] [Related]
4. Expanding the Applicability of the Metal Labeling of Biomolecules by the RIKEN Click Reaction: A Case Study with Gallium-68 Positron Emission Tomography.
Nakamoto Y; Pradipta AR; Mukai H; Zouda M; Watanabe Y; Kurbangalieva A; Ahmadi P; Manabe Y; Fukase K; Tanaka K
Chembiochem; 2018 Oct; 19(19):2055-2060. PubMed ID: 30066425
[TBL] [Abstract][Full Text] [Related]
5. The next generation of positron emission tomography radiopharmaceuticals in oncology.
Rice SL; Roney CA; Daumar P; Lewis JS
Semin Nucl Med; 2011 Jul; 41(4):265-82. PubMed ID: 21624561
[TBL] [Abstract][Full Text] [Related]
6. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP
Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the RGD Motif-Containing α
Roesch S; Lindner T; Sauter M; Loktev A; Flechsig P; Müller M; Mier W; Warta R; Dyckhoff G; Herold-Mende C; Haberkorn U; Altmann A
J Nucl Med; 2018 Nov; 59(11):1679-1685. PubMed ID: 29674419
[TBL] [Abstract][Full Text] [Related]
8. Strategies for improving stability and pharmacokinetic characteristics of radiolabeled peptides for imaging and therapy.
Abbasi Gharibkandi N; Conlon JM; Hosseinimehr SJ
Peptides; 2020 Nov; 133():170385. PubMed ID: 32822772
[TBL] [Abstract][Full Text] [Related]
9. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
10. Methods to Increase the Metabolic Stability of (18)F-Radiotracers.
Kuchar M; Mamat C
Molecules; 2015 Sep; 20(9):16186-220. PubMed ID: 26404227
[TBL] [Abstract][Full Text] [Related]
11. Development of PEGylated peptide probes conjugated with (18)F-labeled BODIPY for PET/optical imaging of MT1-MMP activity.
Kondo N; Temma T; Deguchi J; Sano K; Ono M; Saji H
J Control Release; 2015 Dec; 220(Pt A):476-483. PubMed ID: 26578437
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Preclinical Evaluation of Three Novel Fluorine-18 Labeled Radiopharmaceuticals for P-Glycoprotein PET Imaging at the Blood-Brain Barrier.
Savolainen H; Cantore M; Colabufo NA; Elsinga PH; Windhorst AD; Luurtsema G
Mol Pharm; 2015 Jul; 12(7):2265-75. PubMed ID: 26043236
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Preclinical Evaluation of the First Carbon-11 Labeled PET Tracers Targeting Substance P
Pekošak A; Bulc JŽ; Korat Š; Schuit RC; Kooijman E; Vos R; Rongen M; Verlaan M; Takkenkamp K; Beaino W; Poot AJ; Windhorst AD
Mol Pharm; 2018 Nov; 15(11):4872-4883. PubMed ID: 30335399
[TBL] [Abstract][Full Text] [Related]
14. Rapid solid phase synthesis and biodistribution of 18F-labelled linear peptides.
Sutcliffe-Goulden JL; O'Doherty MJ; Marsden PK; Hart IR; Marshall JF; Bansal SS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):754-9. PubMed ID: 12029548
[TBL] [Abstract][Full Text] [Related]
15. Gallium-68 in Medical Imaging.
Martiniova L; Palatis L; Etchebehere E; Ravizzini G
Curr Radiopharm; 2016; 9(3):187-207. PubMed ID: 27804868
[TBL] [Abstract][Full Text] [Related]
16. [PET radiopharmaceuticals: novelties and new possibilities].
Környei J; Mikecz P; Tóth G
Magy Onkol; 2014 Dec; 58(4):245-50. PubMed ID: 25517442
[TBL] [Abstract][Full Text] [Related]
17. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
18. Site-Selective, Late-Stage C-H
Yuan Z; Nodwell MB; Yang H; Malik N; Merkens H; Bénard F; Martin RE; Schaffer P; Britton R
Angew Chem Int Ed Engl; 2018 Sep; 57(39):12733-12736. PubMed ID: 30086209
[TBL] [Abstract][Full Text] [Related]
19. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
20. Carbon-11 and fluorine-18 chemistry devoted to molecular probes for imaging the brain with positron emission tomography.
Dollé F
J Labelled Comp Radiopharm; 2013; 56(3-4):65-7. PubMed ID: 24285311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
